Q4 Earnings Forecast for Exelixis Issued By Zacks Research

Key Points

• Zacks Research has reduced its Q4 2025 EPS forecast for Exelixis to $0.56 per share, down from a previous estimate of $0.57, amidst overall bearish sentiment.
• Exelixis reported earnings of $0.75 per share for Q3 2025, exceeding expectations, but revenue declined by 10.8% year-over-year to $568.26 million.
• The stock currently holds a consensus rating of "Moderate Buy" and a target price of $44.06 following mixed analyst assessments.

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Zacks Research lowered their Q4 2025 earnings estimates for Exelixis in a report issued on Monday, August 18th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of $0.56 per share for the quarter, down from their previous estimate of $0.57. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' Q1 2026 earnings at $0.54 EPS, Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.63 EPS, FY2026 earnings at $2.49 EPS, Q1 2027 earnings at $0.65 EPS, Q2 2027 earnings at $0.76 EPS and FY2027 earnings at $3.10 EPS.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.63 by $0.12. The firm had revenue of $568.26 million for the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company's quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS.

A number of other research firms also recently issued reports on EXEL. JMP Securities reaffirmed a "market outperform" rating and set a $50.00 price target on shares of Exelixis in a research note on Tuesday, July 29th. Truist Financial decreased their price target on shares of Exelixis from $56.00 to $49.00 and set a "buy" rating on the stock in a research note on Tuesday, July 29th. Stifel Nicolaus upped their price target on shares of Exelixis from $38.00 to $41.00 and gave the company a "hold" rating in a research note on Tuesday, July 29th. Jefferies Financial Group set a $50.00 price target on shares of Exelixis and gave the company a "buy" rating in a research note on Tuesday, June 24th. Finally, Citigroup upped their price target on shares of Exelixis from $45.00 to $56.00 and gave the company a "buy" rating in a research note on Thursday, May 15th. Thirteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.06.

Exelixis Stock Up 0.6%

Exelixis stock traded up $0.23 during mid-day trading on Thursday, reaching $38.13. 458,377 shares of the company's stock traded hands, compared to its average volume of 3,018,857. The company has a market cap of $10.26 billion, a price-to-earnings ratio of 18.33, a PEG ratio of 0.80 and a beta of 0.29. The stock has a 50 day moving average of $41.48 and a two-hundred day moving average of $39.40. Exelixis has a 12-month low of $25.12 and a 12-month high of $49.62.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Coppell Advisory Solutions LLC bought a new position in shares of Exelixis in the fourth quarter worth about $25,000. Hemington Wealth Management lifted its stake in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 522 shares during the period. Colonial Trust Co SC lifted its stake in Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 765 shares during the period. Byrne Asset Management LLC lifted its stake in Exelixis by 129.0% in the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 400 shares during the period. Finally, Luminist Capital LLC lifted its stake in Exelixis by 2,740.0% in the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 685 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Exelixis news, Director Jack L. Wyszomierski sold 7,535 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total transaction of $324,683.15. Following the transaction, the director owned 358,882 shares in the company, valued at $15,464,225.38. The trade was a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sue Gail Eckhardt sold 18,838 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $42.74, for a total transaction of $805,136.12. Following the transaction, the director owned 21,380 shares in the company, valued at $913,781.20. This trade represents a 46.84% decrease in their position. The disclosure for this sale can be found here. Insiders own 2.82% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.